Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Lower Risk MDS or MDS/MPN
NCT05732961Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2023
- Primary completion
- Mar 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), anemia, sponsored by Moffitt Cancer Center. Started Feb 2023; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)anemia
Beyond the preview
Go deeper on NCT05732961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732961.